Seven trends in the global biopharmaceutical industry are forecast for 2021 under the new crown outbreak

So, for now, how will the new global crown outbreak go in 2021? Which area is most popular with big drug companies? What are the investment and financing trends in the pharmaceutical industry? GEN, the world's most-influenced journal in biotechnology, has made seven trend forecasts for 2021 through interviews and observations.
01 New Crown Outbreak: Seeing the End of December 11, 2020, the FDA urgently approved the new Crown Vaccine jointly developed by Pfizer and BioNtech, and by the end of December, 1.8934 million people had been vaccinated On December 18th the FDA approved a similar application for the Moderna vaccine, while on December 30th a new crown vaccine developed jointly by AstraZeneta and Oxford University was approved in the UK and universal vaccination began on January 4th.
antiviral drugs were also urgently approved in 2020.
October 22, 2020, Gilead's Redsyway was approved by the FDA to treat new coronavirus infections in adults and children 12 years of age.
redsiweiser was granted fda emergency use as early as May, with global sales of $873 million in the third quarter.
another treatment for the new coronavirus drug, regenerative antibody REGEN-COV2, was granted an emergency authorization in November, with Regenerative Meta's third-quarter report showing sales of $40.2 million.
In China, on December 30, the State Drug Administration approved the application for the listing of the new crown vaccine for the national drug, and then at the joint anti-control conference, Zeng Yixin, deputy director of the National Health And Wellness Commission and head of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, said that the new crown virus vaccine will be provided free of charge to the whole population.
the number of people vaccinated is expected to increase nearly 150-fold, from 35 million in the fourth quarter of 2020 to 5 billion in the fourth quarter of 2021, with the approval of a variety of new vaccines, according to a study released by analysts.
the problem, where is the market space for anti-neoviral drugs after several vaccines are approved around the world in 2021? Who will support the antiviral drugs under study, or will they continue to be studied in preparation for the next "Great Plague"? 02 Gene therapy: Gene therapy is the most likely area of concern for large pharmaceutical companies, big deals and patient deaths If any of the areas of concern to big drug companies in 2020 are bound to continue fermentation in 2021.
October 2020, Bayer announced its proposed $4 billion acquisition of AskBio.
AskBio has a platform for gene therapy technology, with a clinical product line that includes treatments for Pompeia, Parkinson's disease and congstive heart failure, as well as undocumented clinical adaptations to haemophilia and Duchyn's muscular dystrophy.
same month, Novartis bought Vedrere Bio, an eye gene therapy developer, for $280 million, and Roche signed a $1.8 billion contract with Dyno Therapeutics to use the latter's technology platform to develop adenovirus (AAV) vectors for gene therapy for central nervous system (CNS) disease and liver targeted therapy.
On December 15th Lilly and Prevail announced a deal to buy Prevail for $1.04 billion, a company dedicated to developing potential adenopathic virus-based 9 vector gene therapy for patients with neurodegenerative diseases.
but gene therapy has also attracted attention for four patient deaths in 2020, with two deaths from high-dose AT132 gene therapy reported by Astellas in May and June, and another in August by Astellas In October, Lysogene announced the death of a five-year-old girl with TYPE IIIA adhesive polysaccharose storage disorder (MPS IIIA) in a clinical trial of LYS-SAF302's AAV gene therapy.
clinical trials are still on hold and the direction of 2021 is not accurately predicted.
even so, according to Alliance for Research and Medicine, financing grew 114 per cent between January 2020 and September 2020 to $12bn.
03 Gene Editing: In November 2020, Lilly teamed up with gene editing company Precision BioSciences for a potentially $2.7 billion partnership to open the way for gene therapy for Duchy muscular dystrophy (DMD).
business research firm released a market report on November 20 predicting that the global CRISPR technology market will grow from $1.65 billion in 2020 to $2.57 billion in 2023 and then jump to $6.7 billion by 2030.
abroad, CRISPR technology is considered a biomedical development match between China and the United States, known as sputnik 2.0 competition, with the United States holding 872 CRISPR-related patent applications, followed by China at 858, according to Science.
04 Investment and financing: A large amount of money flowed into the domestic pharmaceutical industry in 2020, the unprecedented year 75 enterprises carried out IPOs, 2.68 times the previous year, despite the outbreak, but the amount of investment and financing for the whole year did not decline significantly, a total of 135 billion yuan in 2020 and 164.982 billion yuan in 2019.
abroad, GEN magazine concludes that there will be significant capital flows to biopharmaceutical companies in 2020 and strong growth in mergers and acquisitions and IPOs, a trend that will continue in 2021.
PwC and CB Insights reported a record $5.9 billion in investments in biopharmaceutical-related industries in the third quarter of 2020, including $3.9 billion in 104 deals in biotechnology alone, more than double the $1.9 billion in 74 deals in the third quarter of 2019.
IPO market is also showing strong strength in 2020.
. Nasdaq raised $9.32 billion in 51 IPOs in the first three quarters of 2020, more than double the $3.6 billion raised in the first three quarters of 2019, according to
Evaluate Pharma.
overall, biotechnology stocks will continue to grow over 2020.
as of November 20, the Nasdaq Biotechnology Index was at 4,364.15, up 22 percent from 3,581.05 a year earlier.
note that in December 2020, Tiantian and Legendary Creatures were included in the NASDAQ Biotechnology Index.
05 Drug Development: Whether a new drug for Alzheimer's has attracted the attention of the biopharmaceutical community abroad, and the new drug aducanumab, which has undergone twists and turns in 2020, has finally submitted a listing application, but there is also speculation that the drug will not be approved in 2021, and Bai Jian's prediction is that it will be approved by the FDA on March 7, 2021.
In November 2020, the FDA's Advisory Committee on Peripheral and Central Nervous System Drugs refused to approve aducanumab because FDA-approved drugs typically require two effective studies with supporting evidence, and only one of the drug's two Phase III clinical trials has shown positive results.
06 Cell Therapy: Financing is growing at an alarming rate in 2020, and MNC is also hitting the gold in cell therapy.
September, Takeda announced that it would cut costs by about $2 billion a year by the end of 2021 to focus on research and development of drugs for tumors and rare diseases, a strategy key to a new generation of cell therapies.
has opened a more than 2,000-square-meter research and development center in Boston, which will be responsible for the clinical development of three ongoing pipeline projects, with the other two projects expected to enter clinical development by the end of 2021; In October, Astellas announced that it would spend $120 million to open a research and development center focused on cell therapy in Massachusetts; in November, Sanofi acquired Kidis Pharma, a Dutch cell therapy company, for a total of 308 million euros ($358 million) to acquire the latter's NK (natural killer) cell platform and products.
for cell therapy is growing at an alarming rate.
, according to Alliance for Regenerative Medicine , funding for cell therapy reached $11 billion in the year to November 2020 , up 242 percent from the same period last year .
phase I clinical trials of cell therapy increased from 41 to 50.
, cell therapy is opening a new chapter.
, Fosun Pharma's revival of Kate CAR-T product FKC876 market application entered the administrative approval stage, is expected to be approved in the near future, which will become the first CAR-T therapy products.
Of course, the price of CAR-T products, and even cell therapy, is still controversial, with Novart's Kymriah, the world's first CAR-T product, charging $475,000 ($3.078 million) in one-time fees, still a high treatment fee for the average patient.
07 Synthetic Biology: The potential of synthetic biology revolves around the logic of life, using the laws and workings to manually "transform" organisms to give them the functions and value they need.
of synthetic biology in the first half of 2020, compared with $1.9 billion in the same period in 2019, according to SynBioBeta.
, of course, the growth of synthetic biology comes from its diverse range of technical applications, including cell therapy, gene therapy, and CRISPR.
CB Insights analysis, the global synthetic biology market will reach $5.3 billion in 2019.
expects the synthetic biology market to grow at a cagency rate of 28.8% to $18.9 billion by 2024, compared to 2019.